<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003685.pub2" GROUP_ID="MUSKEL" ID="414201010615393019" MERGED_FROM="" MODIFIED="2010-05-25 15:50:06 -0400" MODIFIED_BY="Michelle Foote" REVIEW_NO="C074-R" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2010-05-25 15:50:06 -0400" MODIFIED_BY="Michelle Foote">
<TITLE>Rofecoxib for rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="14935" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Garner</LAST_NAME>
<SUFFIX>BPharm PhD MRPharms</SUFFIX>
<POSITION>Technical Advisor</POSITION>
<EMAIL_1>sarah.garner@nice.nhs.uk</EMAIL_1>
<EMAIL_2>SGarner@nice.nhs.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Appraisals Team</DEPARTMENT>
<ORGANISATION>National Institute for Clinical Excellence</ORGANISATION>
<ADDRESS_1>MidCity Place</ADDRESS_1>
<ADDRESS_2>71 High Holborn</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC1V 6NA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 207 0675887</PHONE_1>
<PHONE_2/>
<FAX_1>+44 207 0619787</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-05-25 15:50:06 -0400" MODIFIED_BY="Michelle Foote">
<PERSON ID="14935" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Garner</LAST_NAME>
<SUFFIX>BPharm PhD MRPharms</SUFFIX>
<POSITION>Technical Advisor</POSITION>
<EMAIL_1>sarah.garner@nice.nhs.uk</EMAIL_1>
<EMAIL_2>SGarner@nice.nhs.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Appraisals Team</DEPARTMENT>
<ORGANISATION>National Institute for Clinical Excellence</ORGANISATION>
<ADDRESS_1>MidCity Place</ADDRESS_1>
<ADDRESS_2>71 High Holborn</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC1V 6NA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 207 0675887</PHONE_1>
<PHONE_2/>
<FAX_1>+44 207 0619787</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14929" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Dogan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fidan</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Health Economist</POSITION>
<EMAIL_1>df@doganweb.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Health Economics Unit</DEPARTMENT>
<ORGANISATION>Aventis Pharma Ltd.</ORGANISATION>
<ADDRESS_1>Flat 8</ADDRESS_1>
<ADDRESS_2>291 Boardwalk Place</ADDRESS_2>
<CITY>London</CITY>
<ZIP>E14 56E</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 7801 546758</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0) 2070 932453</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14931" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Ruth</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>Frankish</LAST_NAME>
<SUFFIX/>
<POSITION>Information Specialist</POSITION>
<EMAIL_1>ruth.frankish@nice.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Appraisals Team</DEPARTMENT>
<ORGANISATION>National Institute for Clinical Excellence</ORGANISATION>
<ADDRESS_1>11 Strand</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1N 5HR</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>44-020-77669191</PHONE_1>
<PHONE_2/>
<FAX_1>44-020-77669123</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7D89FCA582E26AA20029B854A42545FC" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Judd</LAST_NAME>
<SUFFIX>MSc</SUFFIX>
<POSITION>Senior Program Officer</POSITION>
<EMAIL_1>maria.judd@chsrf.ca</EMAIL_1>
<EMAIL_2>mgjudd@yahoo.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Research Use/Agente principale de programme, Utilisation de la Recherche</DEPARTMENT>
<ORGANISATION>Canadian Health Services Research Foundation/Fondation canadienne de la recherche sur les services de santé</ORGANISATION>
<ADDRESS_1>1565 avenue Carling Avenue</ADDRESS_1>
<ADDRESS_2>Suite/pièce 700</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Z 8R1</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-728-2238 ext/poste 250</PHONE_1>
<PHONE_2/>
<FAX_1>613-728-3527</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5472" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tanveer</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Towheed</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>tt5@queensu.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine and of Community Health and Epidemiology</DEPARTMENT>
<ORGANISATION>Queen's University</ORGANISATION>
<ADDRESS_1>Etherington Hall-Room 2066</ADDRESS_1>
<ADDRESS_2/>
<CITY>Kingston</CITY>
<ZIP>K7L 3N6</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+ 1 613 533 6896</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 533 2189</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>elacasse@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health, Department of Medicine</DEPARTMENT>
<ORGANISATION>Ottawa Hospital</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Research Reference Centre</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-05-19 18:52:49 -0400" MODIFIED_BY="Lara Maxwell">
<UP_TO_DATE>
<DATE DAY="17" MONTH="11" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="11" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="11" YEAR="2006"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-19 18:54:08 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-05-19 18:54:08 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. CMSG ID C074-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>National Institute for Clinical Excellence</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Institute for Population Health, University of Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Rofecoxib for rheumatoid arthritis</TITLE>
<SUMMARY_BODY>
<P>
<B>Editor's note: The anti-inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long-term use (greater than 18 months) could increase the risk of heart attack and stroke. Further information is available at www.vioxx.com.</B>
</P>
<P>
<B>Does rofecoxib work to treat rheumatoid arthritis and how safe is it? </B>
<BR/>To answer this question, scientists working with the Cochrane Musculoskeletal Group found and analyzed two high quality studies. These studies include over 8700 people with rheumatoid arthritis (RA) and about 80% were women. Most people received 25 or 50 mg of rofecoxib once a day over 8 weeks or 9 months. These studies provide the best evidence we have today. </P>
<P>
<B>What is rofecoxib (Vioxx)?</B>
<BR/>Rofecoxib (Vioxx) is often referred to as a 'COX II inhibitor' and is one of the new non-steroidal anti-inflammatory drugs (NSAIDs) prescribed to decrease pain and inflammation in rheumatoid arthritis. Other NSAIDS, such as naproxen (Naprosyn) are also prescribed but they come with warnings that they may cause digestive side effects such as ulcers, bleeds and perforations that can be serious. Rofecoxib is thought to be safer on the stomach than other NSAIDS but can be more expensive.</P>
<P>Rofecoxib was taken off the market at the end of September 2004. A study had shown that people taking rofecoxib to prevent colon cancer had more heart attacks and strokes than people taking a sugar pill.</P>
<P>
<B>How well does it work?</B>
<BR/>The studies show that more people with RA who took rofecoxib for 8 weeks had relief from their symptoms than people who took a 'sugar pill' or placebo. In fact, people showed a 20% improvement in the number of tender and swollen joints plus a 20% improvement in at least three out of five other measures such as the level of pain they reported, the level of disease activity they described, their ability to do everyday activities, their physical check-up and their results on blood tests. </P>
<P>It was also found that 25 mg of rofecoxib worked just as well as 50 mg over 8 weeks.</P>
<P>The studies also show that rofecoxib worked just as well as naproxen over 9 months. </P>
<P>
<B>How safe is it?</B>
<BR/>Fewer people taking rofecoxib for 9 months had ulcers and bleeds than people who took naproxen. But more people stopped taking rofecoxib than placebo because of its side effects.</P>
<P>The 9 month study showed that rofecoxib and naproxen caused a similar number of kidney difficulties, but that rofecoxib caused more heart problems such as heart attacks. The reason for the heart problems is not clear at this time.</P>
<P>
<B>What is the bottom line?</B>
</P>
<P>Rofecoxib at 50 mg (which is two times the recommended dose) works just as well as 1 gram of naproxen to reduce pain and inflammation in RA. It is safer on the stomach than naproxen for 9 months, but it is uncertain whether it is safer in the long term. </P>
<P>Heart problems, such as heart attacks occurred in more people taking 50 mg of rofecoxib for 9 months than people taking naproxen and therefore caution is recommended for people who have a greater risk of heart problems. </P>
<P>More studies need to be done to test the cost-effectiveness and the long term effects of rofecoxib.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>
<B>Editor's note: The anti-inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long-term use (greater than 18 months) could increase the risk of heart attack and stroke. Further information is available at www.vioxx.com.<BR/>
</B>
<BR/>Rheumatoid arthritis (RA) is a systemic auto-immune disorder, in which the synovial lining of many joints and tendon sheaths are persistently inflamed.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the efficacy and toxicity of rofecoxib for treating RA.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the following electronic databases up to December 2000: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, National Research Register, NHS Economic Evaluation Database, Health Technology Assessment database. The bibliographies of retrieved papers were scanned for additional references. The manufacturers of rofecoxib, MSD, were also approached by the UK National Institute for Clinical Excellence to submit additional evidence to inform it's appraisal on the use of cyclo-oxygenase inhibitors for arthritis.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included randomised controlled trials of parallel group design evaluating the efficacy and/or toxicity of rofecoxib in RA, both placebo based and comparative trials were eligible. Relevant outcome criteria had to be available to evaluate efficacy and/or toxicity, such as the OMERACT outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were abstracted independently by two reviewers and the results were compared for the degree of agreement. A validated tool (Jadad 1996) was used to score the quality of the randomised controlled trials. The planned analysis was to pool, where appropriate, continuous outcome measures using mean or standardized mean differences, and dichotomous outcome measures using relative risk ratios. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two randomised controlled trials evaluating rofecoxib for the treatment of RA were identified and met the inclusion criteria. One compared rofecoxib to placebo and was designed to assess the safety and efficacy of several doses of rofecoxib. The second trial compared rofecoxib to naproxen and was primarily designed to assess the safety of rofecoxib so did not include all the recommended RA efficacy measures. The overall number of ACR 20 responders who had received 25mg (82/ 171 = 48%) or 50mg (86/161 = 53%) was statistically significantly more than those receiving placebo (58/168 = 35% ) (RR 1.39 CI: 1.07, 1.80 and RR 1.55 CI: 1.20, 1.99 respectively) with no statistically significant differences between the 25 and 50 mg doses. The safety profile of rofecoxib was similar to that of placebo. In the comparative trial, rofecoxib at a dosage of 50 mg/day demonstrated similar efficacy to naproxen at a dosage of 500 mg twice daily. However, the combined rate of clinically significant complicated gastro-intestinal events (GI) (perforations, ulcers, bleeds, or obstructions) was lower with rofecoxib than with naproxen (RR 0.46, 95% CI, 0.34 to 0.63) due to a reduction in the number of ulcers and bleeds. Compared to patients taking naproxen, patients taking rofecoxib had a greater risk of having any cardiovascular event (45/4047 = 1.1% vs 19/4029 =0.47%) (RR 2.36 CI 1.38 to 4.02) and had greater risk of having a non-fatal myocardial infarction (MI) (18/4047 =0 .44% and 4/4029 =0.1%) (RR 4.48, 95% CI, 1.52 to 13.23).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>In patients with RA, rofecoxib demonstrates a greater degree of efficacy than placebo, while having a comparable safety profile. Rofecoxib demonstrates a similar degree of efficacy as naproxen, but with a significantly lower rate of ulceration and gastrointestinal bleeding. Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear.</P>
<P>Rofecoxib was voluntarily withdrawn from global markets in October 2004. It cannot therefore be prescribed and therefore there are no implications for practice concerning its use. None the less when considering which NSAID to use, it must be borne in mind that the toxicity of NSAIDs is variable amongst patients and drugs and it tends to be dose related and associated with variation in the mode of action, absorption, distribution and metabolism.There remains a number of questions over both the benefits and risks associated with Cox II selective agents and further work is ongoing. It is likely that this issue will not be resolved until research has enabled a fuller understanding of the complex mechanism by which the Cox system operates.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Rheumatoid arthritis (RA) is a systemic auto-immune disorder, characterised by widespread and persistent inflammation of the synovial lining of the joints and tendon sheaths. RA affects around 0.5% to 1% of the population worldwide (<LINK REF="REF-Silman-1998" TYPE="REFERENCE">Silman 1998</LINK>). Recent estimates in Western populations indicate an annual incidence of 0.5 per 1000 population. Due to the long duration of the disease, the prevalence is much higher at 8 per 1000 population. The typical age of onset is 20 to 45 years of age and over 75% of patients are female (<LINK REF="REF-Silman-1998" TYPE="REFERENCE">Silman 1998</LINK>).</P>
<P>The disease itself is incurable but control of inflammation and associated symptoms such as pain and stiffness can improve quality of life and delay disease progression. Non-drug strategies are used initially, including patient education, dietary advice, physiotherapy and occupational therapy. Non steroidal anti-inflammatory drugs (NSAIDs) have been important in the management of RA for the past century. Since the 1980's NSAIDs have been used in addition to adjunct disease-modifying antirheumatic drugs (DMARDS). NSAIDs continue to play an important role in reducing pain and inflammation in RA, but they cause important gastrointestinal side effects. These include perforations, ulcers and bleeding, which can threaten life and cause serious morbidity. </P>
<P>The primary site of NSAID action is the cyclo-oxygenase enzyme that converts arachidonic acid into prostaglandins, which amongst other functions mediate inflammation and pain. Two forms of this enzyme have been described Cox I and Cox II (<LINK REF="REF-Vane-1998" TYPE="REFERENCE">Vane 1998</LINK>). Cox I is normally present in high concentrations in platelets, vascular endothelial cells, stomach and kidney collecting tubules, and is responsible for the production of prostaglandins that are essential for maintenance of normal endocrine and renal function, gastric mucosal integrity and hemostasis. In contrast, Cox II is virtually undetectable in most tissues under physiological conditions but its activity may be dramatically up-regulated by inflammatory and mitogenic stimuli, which suggests that it plays an important role in the mediation of inflammation (<LINK REF="REF-Vane-1998" TYPE="REFERENCE">Vane 1998</LINK>). Sites of inducible Cox II expression include rheumatoid synoviocytes, macrophages and polymorphonuclear leukocytes (<LINK REF="REF-Vane-1998" TYPE="REFERENCE">Vane 1998</LINK>). </P>
<P>The gastrointestinal adverse events associated with NSAIDs are thought to be due at least in part to inhibition of the Cox I isoform and it was hypothesised that the selective inhibition of Cox II could reduce their incidence, whilst maintaining the therapeutic efficacy. This led to the development of a new class of NSAID- the coxibs, so far includes rofecoxib, celecoxib and valdecoxib. In addition, the relative inhibitory profiles of standard NSAIDs against the cyclooxygenase isoforms differ, and whilst the absolute figures vary depending on the assay technique, the standard NSAIDS etodolac, meloxicam and nimisulide show increased selectivity for Cox II.</P>
<P>Therefore, it seemed possible that the introduction of selective cyclo-oxygenase 2 (COX-II) inhibitors might improve the safety of traditional NSAID use in patients with RA. In OA, dosages of 12.5 mg/day to 25 mg/day have been shown to be beneficial, compared to placebo. However, in contrast with OA, RA is associated with a greater degree of joint inflammation, and therefore, higher dosages of rofecoxib (25 mg/day to 50 mg/day) have been tested in the clinical trials.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the clinical efficacy and safety of rofecoxib in treating RA by systematic review of available evidence. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Prospective randomised controlled trials (RCTs) of parallel design. Open trials were included, if their results could be interpreted with respect to their inherent potential for bias. No studies were excluded on the basis of language of publication.</P>
<P>Studies were to be excluded that had fewer than 50 patients in each arm, duration of treatment of less than four weeks or used concomitant intra-articular corticosteroid therapy.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Individuals with RA with no restrictions for age or sex.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Rofecoxib versus either placebo or another NSAID. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Studies were included if any accepted method to assess disease severity or progression was used. The ACR core set of disease activity measures for RA clinical trials which were endorsed by the European League Against Rheumatism (EULAR) and the Outcome Measures for Rheumatoid Arthritis Clinical Trials (OMERACT) were particularly sought (<LINK REF="REF-OMERACT-1993" TYPE="REFERENCE">OMERACT 1993</LINK>, <LINK REF="REF-Felson-1993" TYPE="REFERENCE">Felson 1993</LINK>). </P>
<P>EFFICACY MEASURES:<BR/>OMERACT outcomes: <BR/>(1) number of tender joints per patient<BR/>(2) number of swollen joints per patient<BR/>(3) pain<BR/>(4) physician global assessment<BR/>(5) patient global assessment<BR/>(6) functional status<BR/>(7) acute phase reactants<BR/>(8) radiological damage</P>
<P>Definition of improvement:<BR/>The issue of statistical versus clinical significance in clinical trials is relevant to clinical care. Based on the set of efficacy measures outlined above the following definition of clinical improvement has been established (<LINK REF="REF-Felson-1995" TYPE="REFERENCE">Felson 1995</LINK>, <LINK REF="REF-Pincus-1999" TYPE="REFERENCE">Pincus 1999</LINK>). </P>
<P>An ACR 20 response represents a 20% improvement in tender and swollen joints counts plus a 20% improvement in 3 of the 5 following remaining core measures: patient and physical global assessments, pain, functional status and an acute phase reactant. </P>
<P>SAFETY MEASURES:<BR/>Data were also collected on the number of (incidence and severity of ):<BR/>1) total withdrawals<BR/>2) withdrawals due to total AEs <BR/>3) withdrawals due to gastro-intestinal AEs (GI AEs) <BR/>4) withdrawals due to lack of efficacy<BR/>5) total adverse events (AEs) associated with therapy<BR/>-Oedema, hypertension, myocardial infarction, renal function - found<BR/>6) number of patients with cardiovascular event(s) <BR/>7) number of patients with perforations and/or ulcer and/or bleed (PUBs)<BR/>Ulcers detected by endoscopy were considered separately from ulcers presenting clinically.<BR/>8) number of patients with perforation and/or obstruction and/or bleeding (POBs) <BR/>9) Deaths</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>MEDLINE (1966 to December 2000), EMBASE (1980 to December 2000), Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register (CCTR) (Issue 4: 2000), National Research Register (NRR), NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) database , HEED were all used to identify trials of rofecoxib in RA patients. Web searches for relevant systematic reviews or guidelines were undertaken and The Cochrane Collaboration trial and CRD economic evaluation filters were used. The bibliographies of retrieved reviews were scanned for additional references. The UK National Institute for Clinical Excellence approached the manufacturers (MSD) to submit any additional/unpublished data as part of its appraisal process and the submissions were scanned for relevant additional studies and abstracts. </P>
<P>MEDLINE search<BR/>1. (cyclooxygenase-2 or cyclooxygenase 2 or cyclooxygenase-II or cyclooxygenaseII).ti,ab.<BR/>2. (cyclo oxygenase-2 or cyclo oxygenase2 or cyclo oxygenase-II or cyclo oxygenaseII).ti,ab.<BR/>3. (cox-2 or cox2 or cox-II or coxII).ti,ab.<BR/>4. (rofecoxib or vioxx or MK-0966).af<BR/>5. Cyclooxygenase inhibitors/<BR/>6. or/1-5<BR/>7. exp *arthritis/<BR/>8. (arthrit$ or osteoarthrit$).ti,ab.<BR/>9. 7 or 8<BR/>10.6 and 9</P>
<P>Embase search<BR/>1. (cyclooxygenase-2 or cyclooxygenase2 or cyclooxygenase-II or cyclooxygenaseII).ti,ab.<BR/>2. (cyclo oxygenase-2 or cyclo oxygenase2 or cyclo oxygenase-II or cyclo oxygenaseII).ti,ab.<BR/>3. (cox-2 or cox2 or cox-II or coxII).ti,ab.<BR/>4. (rofecoxib or vioxx or MK-0966).af.<BR/>5. Cyclooxygenase 2 inhibitor/<BR/>6. Cyclooxygenase 2/<BR/>7. Rofecoxib/<BR/>8. or/1-7<BR/>9. (arthrit$ or osteoarthrit$).ti,ab.<BR/>10. exp Arthritis/<BR/>11. 9 or 10<BR/>12. 8 and 11</P>
<P>Cochrane Library/CCTR<BR/>1. (CYCLOOXYGENASE* near INHIBITOR*<BR/>2. (CYCLO next OXYGENASE*) near INHIBITOR*<BR/>3. COX* near INHIBITOR* <BR/>4. ROFECOXIB or VIOXX<BR/>5. CYCLOOXYGENASE-INHIBITORS:ME <BR/>6. #1 or #2 or #3 or #4 or #5 <BR/>7. ARTHRITIS or OSTEOARTHRITIS<BR/>8. ARTHRITIS*:ME<BR/>9. (#7 or #8) <BR/>10.(#9 and #10) </P>
<P>The titles and abstracts identified by the searches were assessed, using an over inclusive approach so as not to miss potentially relevant reports.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>STUDY SELECTION AND DATA EXTRACTION<BR/>Two reviewers (SG, DF) independently ascertained whether each study met the inclusion criteria for the review and a double abstraction process was undertaken. Any discrepancies were resolved by discussion and where this was not possible the authors of the study were contacted for clarification. Duplicate publications of the same study were considered in tandem with the original publication.</P>
<P>QUALITY ASSESSMENT<BR/>The methodological quality of the included studies was assessed by independent reviewers (MJ, BS) on the basis of randomisation, adequate concealment of randomisation, degree of blinding, use of intention to treat analysis and description of dropouts and withdrawals. The Jadad and Schultz validated assessment tools (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>, <LINK REF="REF-Schultz-1995" TYPE="REFERENCE">Schultz 1995</LINK>) were used to assign an overall quality score to each study. </P>
<P>DATA ANALYSIS<BR/>The initial aim of the review was to statistically pool the results of the individual studies for each of the interventions to produce an overall estimate of effect. However, the paucity of studies meant that this could not be undertaken. The studies have been presented separately and where possible data from intention to treat (ITT) analysis were abstracted. Results are presented in both absolute and relative terms and are presented as relative risks (RR) or weighted mean differences (WMD) with their 95% confidence intervals (CI).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Two RCTs met the inclusion criteria for this review, which have been published in full in peer-reviewed journals. Both were double-blind multi centre studies, which enrolled a total of 8,734 patients with RA and compared rofecoxib to placebo (<LINK REF="STD-Schnitzer-1999" TYPE="STUDY">Schnitzer 1999</LINK>) and naproxen (<LINK REF="STD-Bombardier-2000" TYPE="STUDY">Bombardier 2000</LINK>). Full details of the studies can be found in the table of included studies. </P>
<P> A further four unpublished studies were described in a pooled analysis examining cardiovascular events (<LINK REF="REF-Konstam-2001" TYPE="REFERENCE">Konstam 2001</LINK>) and are awaiting assessment (see Studies awaiting assessment). A fifth six-week RCT (CDER017) comparing 125mg, 175 mg rofecoxib and placebo was submitted to the Centre for Drug Evaluation and Research and is also awaiting assessment. The searches revealed one ongoing 52 week RCT, due to report in late 2001(see Ongoing Studies), which compares 25mg, 50mg rofecoxib to placebo in RA.</P>
<P>The placebo controlled trial was a US phase II dose ranging study that lasted eight weeks and included a total of 658 patients over the age of eighteen with no upper age limit (<LINK REF="STD-Schnitzer-1999" TYPE="STUDY">Schnitzer 1999</LINK>). There were no clinically important differences between the study groups at baseline. The overall mean age was 55 and 78% of patients were female. Twenty-nine percent of patients were taking methotrexate and 22% corticosteroids. Rofecoxib (5, 25 or 50 mg per day) was compared to placebo, with randomisation stratified by concomitant methotrexate use. All patients included had to have a history of therapeutic benefit of NSAID use and to have used NSAIDs for a minimum of 25 days out of the previous 30. Wash-out periods varied from 3 to 15 days depending on the elimination half-life of the NSAID. Patients were randomised only if they demonstrate flare on NSAID withdrawal. DMARDs were permitted if the patients had been stabilised for the past six months and in each case up to one third of patients were permitted to continue taking either a corticosteroid or methotrexate, but patients taking both were excluded. Patients were also excluded if they had experienced a recent serious cardiovascular event, serum creatinine &gt;2.0 mg/dL or estimated creatinine clearance &lt;=30ml/min. Paracetamol rescue was permitted up to a maximum of 24 325mg tablets in a 2-week period. Efficacy outcome was assessed by the number of patients meeting the criteria for an ACR 20 response (20% improvement in tender and swollen joint counts and 20% improvement in 3 out 5 remaining ACR core measures) (<LINK REF="REF-Felson-1993" TYPE="REFERENCE">Felson 1993</LINK>). <BR/> <BR/>The international VIGOR study compared rofecoxib 50mg to naproxen 500mg twice daily in 8076 patients aged 50 years or over with a median follow up of nine months (<LINK REF="STD-Bombardier-2000" TYPE="STUDY">Bombardier 2000</LINK>). Patients were permitted to take low-dose H2 receptor antagonists, paracetamol, glucocorticoids or DMARDs but were excluded if they were taking aspirin,ticlopidine, anticoagulants, anti-platelet agents, cyclosporin, misoprostol, sucralfate or proton-pump inhibitors or H2 antagonists at prescription strength. In total, 56% were on a chronic steroid and 56% on methotrexate and about 46 % had a previous history of cardiovascular disease. Patients were excluded if they had a history of cerebrovascular events in the two years before the study; or a myocardial infarction or coronary bypass surgery in the year before the study. 80% of patients were female and the mean age was 58 years. A 14 day washout period was permitted and patients stratified according to the presence or absence of a history of gastroduodenal ulcer, upper GI bleeding and gastroduodenal perforation. The trial was primarily designed to assess the safety of rofecoxib so did not include all the recommended RA efficacy measures. Efficacy was assessed using the Global Assessment of Disease questionnaire answered by the patient and physician and the Modified Health Assessment Questionnaire (mHAQ). The primary endpoint was the number of confirmed upper GI events (gastroduodenal perforation or obstruction, upper GI bleeding and symptomatic gastroduodenal ulcer). Unconfirmed clinically important gastrointestinal events were also reported.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The methodological quality of the included studies was assessed using a validated checklist (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) that rates the appropriateness of randomisation (2 points), appropriateness of double blinding (2 points) and description of dropouts and withdrawals (1 point), the total possible score is five. In addition, concealment allocation was assessed and rated as A (blind randomisation), B (unclear methods of randomisation), or C (quasi-randomisation). Quality was assessed independently by two reviewers (MJ, BS). Differences were resolved by consensus.</P>
<P>Both trials were randomised double blinded trials and included a description of the reasons for dropouts. The <LINK REF="STD-Bombardier-2000" TYPE="STUDY">Bombardier 2000</LINK> paper included a description of the method of double blinding so it received an additional point and a quality score of four. The <LINK REF="STD-Schnitzer-1999" TYPE="STUDY">Schnitzer 1999</LINK> paper received a quality score of three. Concealment of allocation was unclear in both trials therefore both trials received a concealment rating of B.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. EFFICACY<BR/>1.1 ROFECOXIB versus PLACEBO<BR/>Individuals who had received 5mg demonstrated no statistically significant differences in either total withdrawals, withdrawals due to lack of efficacy or response measures from those in the placebo group. The overall number of ACR 20 responders who had received 25mg (82/ 171 = 48%) or 50mg (86/161 = 53%) was statistically significantly more than those receiving placebo (58/168 = 35% ) (RR 1.39 CI: 1.07, 1.80 and RR 1.55 CI: 1.20, 1.99 respectively) with no statistically significant differences between the 25 and 50 mg doses. This trend was evident in the subgroup of the population who were not receiving methotrexate, but the difference did not reach significance in those receiving methotrexate. Similarly, although results were presented only graphically, patients in the 25 and 50 mg groups had significantly greater mean change in pain scores, patient global assessment of disease activity, investigator global assessment of disease activity, Stanford Health Assessment Questionnaire Disability Index and paracetamol use (p&lt;0.001). As the numerical data was not available for these outcomes the authors will be contacted in attempt to obtain it. In the meantime, data will be abstracted using graphical methods. Fewer patients taking rofecoxib 25 or 50mg withdrew because of lack of efficacy compared with those on placebo (6.4 %, 6.8% and 14.3%) (RR 0.45 CI: 0.23, 0.89 and RR 0.48 CI: 0.24, 0.94 respectively) and overall (15.2%, 16.1% and 22.0%) (RR 0.69 CI: 0.44, 1.09 and RR 0.73 CI: 0.47, 1.15). </P>
<P>1.2 ROFECOXIB versus NAPROXEN<BR/>There were no statistically significant differences in efficacy between the two interventions as measured by patient global assessment (rofecoxib group improved by 12.8%, naproxen group improved by 13.2%; weighted mean difference (WMD) was -0.02 CI: -0.06, 0.02), investigator global assessment (rofecoxib group improved by 12.3%, naproxen group improved by 13%; WMD was -0.03 CI: -0.07, 0.01) and the mHAQ [patient reported functioning] (rofecoxib group improved by 3.7%, naproxen group improved by 4%; WMD -0.01 CI: -0.03, 0.01). <BR/>There were no differences in the rates of withdrawal due to lack of efficacy : rofecoxib 6.3%, naproxen 6.5% (RR= 0.97 CI:0.82, 1.14) and overall withdrawal rates were also equivalent 29.3% versus 28.5% (RR 0.03 CI: 0.96, 1.10). </P>
<P>2 SAFETY </P>
<P>2.1 ROFECOXIB versus PLACEBO<BR/>There were no statistically significant differences between the rofecoxib and placebo groups in the number of withdrawals due to adverse events (3.0%, 3.2%, 4.7% and 6.2% in the placebo, rofecoxib 5, 25 and 50mg groups respectively) or withdrawals due to GI adverse events (0%, 1.3%, 1.8% and 0% respectively) . No perforations, ulcers or bleeds (PUBs) were reported during the 8 week study. Adverse event data were only reported for events that greater than 3% of patients in any group experienced, therefore there were no data on overall rates of events or GI events. It was reported that there was a similar incidence of adverse events in all groups except that more individuals experienced rash in the 50mg group. There were also similar incidences of lower extremity oedema (1.2%, 1.3%, 2.3% and 2.5% in the placebo, rofecoxib 5, 25 and 50mg groups respectively) and hypertension (1.2%, 0%, 2.9% and 3.1%). There were little data presented on laboratory values but the authors reported no meaningful differences, although elevated serum creatinine caused discontinuation of one patient in the 25 and 50 mg groups. No data on mortality rates was presented.</P>
<P>2.2 ROFECOXIB versus NAPROXEN<BR/>Overall 16.4% of individuals taking 50mg rofecoxib withdrew due to adverse events compared to 16.1% taking naproxen (RR 1.02 CI: 0.92, 1.12). In total, 7.8% of the rofecoxib group and 10.6% of the naproxen group withdrew due to any GI events ( RR 0.74 CI: 0.64, 0.85). The combined incidence of confirmed upper GI events (perforations, ulcers, bleeds or obstructions) was 1.4% in the rofecoxib group and 3.0% in the naproxen group (RR 0.46 CI: 0.34,0.63) and the combined incidence of complicated confirmed events (perforations, obstructions and severe upper GI bleeding) were 0.4% and 0.9% respectively (RR 0.43 CI: 0.24,0.77). There were 31 individuals with a GI bleed in the rofecoxib group (0.8%) and 82 in the naproxen group (2%) (RR 0.38 CI: 0.25, 0.57) . The relative risk for upper GI bleeding was 0.4 (CI: 0.2,0.7) and for bleeding beyond the duodenum 0.5 (CI: 0.2, 0.9). There were no data reported on the incidence of gastrointestinal symptoms or other adverse events except 1.2 % of individuals in the rofecoxib group experienced renal adverse events compared to 0.9 % in the naproxen group (RR 1.4 CI: 0.9, 2.1), resulting in the withdrawal of 0.2% of patients in each group. A relative risk reduction of 54% for perforations, obstructions and bleeds was demonstrated in rofecoxib 50mg treated patients compared to naproxen 1g and in absolute terms complications affected 0.4% and 0.9% of individuals respectively.</P>
<P>Subgroup analyses of individuals with previous GI events also showed a lower rate of GI events in individuals treated with rofecoxib (RR 0.4 CI: 0.2, 0.8) as did that in those with no previous events (RR 0.5 CI: 0.3, 0.7) and in the 56% of individuals who were receiving glucocorticoid therapy at baseline (RR 0.4 CI: 0.2, 0.6). The risk was not significantly different in the 44% of individuals who were not receiving glucocorticoid therapy (RR 0.7 CI: 0.4, 1.2). Similarly the RR of clinical GI events in H. pylori negative and positive patients was significantly different (p=0.04, data not given). The RR of clinical GI events remained significantly lower in the sub-group of patients with very low risk (&lt;65 years of age, H. pylori negative, no history of clinical GI event and not taking glucocorticoids at baseline) (RR = 0.1 CI: 0.02, 1.0). The authors concluded that 41 patients would have to be treated with rofecoxib in order to avert one clinical upper GI event. </P>
<P>Individuals in the rofecoxib group experienced a significantly higher rate of serious thrombotic CV events. The cardio-vascular death rate was 0.2% in both groups, with an incidence of myocardial infarction of 0.45% in the rofecoxib group compared to 0.1 % in the naproxen group (RR 5.0 CI: 1.5,13.2). 38% of the individuals who experienced a heart attack were in the 4% of individuals who met the criteria for cardioprophylaxis with aspirin ( history of MI, angina, cerebrovascular accident, transient ischemic attack or coronary bypass) but who were not permitted to take aspirin by the study protocol. Other antiplatelet or anticoagulant medications were also prohibited. Patients with a history of MI or bypass within the year immediately preceding the study or cerebrovascular events in the preceding two years were excluded. Additional data submitted to the FDA (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>)showed that 45/ 4047 (1.11%) of rofecoxib patients and 19/4029 (0.47%) naproxen patients had serious thrombotic cardiovascular events (RR 2.36 CI: 1.38, 4.02). </P>
<P>A post-hoc re-examination of the data found that of the total patients 170 individuals in the rofecoxib group and 151 in the naproxen group had indications for aspirin as the need for aspirin was an exclusion criterion for the trial. In these patients the RR was 4.9 (CI: 1.4, 16.9) compared to 1.9 (CI: 1.0, 3.5) in those in whom it was not indicated. This additional data also reports that more rofecoxib individuals developed hypertension compared to those receiving naproxen with greater increases in systolic and diastolic blood pressure. (4.6 mm Hg/ 1.7 mm Hg compared to 1/0.1). The overall mortality rate was similar in the rofecoxib and naproxen groups, 0.5% and 0.4% respectively (<LINK REF="REF-FDA-2001" TYPE="REFERENCE">FDA 2001</LINK>). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>In October 2004, Merck voluntarily withdrew rofecoxib after analysis of an ongoing trial of the use of rofecoxib in 2600 patients for the prevention of adenomatous colon polyps indicated that 3.5% of the patients in the rofecoxib group experienced a myocardial infarction or stroke compared to 1.9% of the patients assigned to placebo (p&lt;0.001). </P>
<P>Further study is needed to examine the efficacy of rofecoxib for the treatment of RA. The VIGOR study showed that rofecoxib at a daily dose of 50mg for 9 months improved patient global assessment of disease activity by 0.5% more than naproxen and patient reported functioning (HAQ score) by 0.33% more than naproxen but this difference was not statistically significant. It is important to also note that 50mg is two times higher than the recommended long term dose of rofecoxib for RA. In addition, efficacy was not measured with the full set of recommended outcomes for RA trials (<LINK REF="REF-Felson-1993" TYPE="REFERENCE">Felson 1993</LINK>, <LINK REF="REF-OMERACT-1993" TYPE="REFERENCE">OMERACT 1993</LINK>). The placebo controlled dose ranging study did include all recommended endpoints for RA trials but was only 8 weeks long.</P>
<P>No data were available on the comparative overall incidence of GI events for rofecoxib and placebo. Whilst no PUBs were reported in either group, eight weeks is not long enough to conclude that rofecoxib is associated with an equivalent risk to placebo in RA patients, especially given the sample size. The results of the VIGOR study show a reduced risk with rofecoxib of confirmed upper GI event ( perforations, obstructions, ulcers, and/or bleeds), complicated confirmed upper GI event (perforation, obstruction and/or bleed), complicated upper GI bleeding (severe upper GI bleeding) and post duodenal bleeding. It also showed a reduction in complicated ulcers among those taking rofecoxib but is unclear how many of these ulcers are clinically important.</P>
<P>The worldwide withdrawal of rofecoxib was the culmination of growing concern over the adverse renovascular effects of rofecoxib that began after the 1999 publication of the 'Vioxx Gastrointestinal Outcomes Research' (VIGOR) trial Bombardier 2000.The data from the VIGOR suggested that, whilst rofecoxib at a dose of 50mg causes fewer GI complications, there seemed to be an increased risk of adverse cardiovascular events. The annualised MI rate in rofecoxib treated patients was 0.74 %. Whist this may suggest that rofecoxib has a prothrombotic effect, interpretation of the results is confounded by the prohibition of cardioprophylactic aspirin in the study and evidence to suggest that naproxen has an antithrombotic effect. Rheumatoid arthritis also increases the risk of MI (<LINK REF="REF-Wallberg-1999" TYPE="REFERENCE">Wallberg 1999</LINK>) and the dose of rofecoxib used is higher than that used routinely for the treatment of OA or the current recommended therapeutic dose for RA. The dose-response relationship has not been investigated and at the time of this update no 25mg data were available. The role of changes in blood pressure in increasing the risk of cardiovascular events also needs to be examined as, whilst only one patient experiencing a MI had coexistent hypertension, rofecoxib has been shown to cause increases in diastolic and systolic blood pressure to a greater extent than celecoxib in hypertensive individuals (<LINK REF="REF-Whelton-2001" TYPE="REFERENCE">Whelton 2001</LINK>). This study also showed increased rates of oedema in rofecoxib treated individuals. It has been demonstrated that a 2mm Hg reduction in diastolic blood pressure is associated with a 40% reduction in stroke rate and 25% reduction in MI rate (<LINK REF="REF-Collins-1999" TYPE="REFERENCE">Collins 1999</LINK>).</P>
<P>Any potential tendency to cause excess CV events is of concern as many arthritic patients are elderly and therefore have increased risk factors. The exclusion criteria for ongoing studies have subsequently been changed to permit the use of aspirin if indicated. The use of aspirin is however a double-edged sword as aspirin increases the risk of PUBs and data from the celecoxib CLASS study suggest that the rate of PUBs in individuals receiving both aspirin and celecoxib is similar to that in individuals receiving standard NSAIDs (<LINK REF="REF-Silverstein-2000" TYPE="REFERENCE">Silverstein 2000</LINK>).</P>
<P>Emerging data have also suggested that the coxibs may cause renal complications. All NSAIDs can cause adverse renal effects that include reductions in glomerular filtration rate, renal blood flow and sodium and potassium excretion, which can lead to fluid retention, oedema, hypertension and hyperkalaemia and in extreme cases renal failure and tubulointerstitial nephritis. Both rofecoxib and celecoxib have been shown to have similar effects to other NSAIDs in producing qualitative changes in urinary prostaglandin excretion, glomerular filtration rate, sodium retention (<LINK REF="REF-Rocha-2001" TYPE="REFERENCE">Rocha 2001</LINK>, <LINK REF="REF-Swan-2000" TYPE="REFERENCE">Swan 2000</LINK>, <LINK REF="REF-Brater-2001" TYPE="REFERENCE">Brater 2001</LINK>). In addition, COX II has been shown to be constitutively expressed in the kidney and may, therefore, be intimately involved in prostaglandin-dependent renal homeostatic processes (<LINK REF="REF-Swan-2000" TYPE="REFERENCE">Swan 2000</LINK>) . To date the findings support an essential role for COX II in the maintenance of renal hemodynamic and electrolyte homeostasis and therefore renal precautions and monitoring apply as much to the coxibs as to other NSAIDs, with predisposed individuals (such as those with congestive heart failure, diuretic use or cirrhosis) experiencing a decrease in GFR. In hypertensive individuals rofecoxib has been shown to cause a greater increase in blood pressure and more oedema than celecoxib ( <LINK REF="REF-Whelton-2001" TYPE="REFERENCE">Whelton 2001</LINK>). The available literature suggests that a full review examining the evidence on renal effects of coxibs is warranted.</P>
<P>To date, two published pooled analyses have examined the incidence of cardiovascular events in rofecoxib treated patients (<LINK REF="REF-Konstam-2001" TYPE="REFERENCE">Konstam 2001</LINK>, <LINK REF="REF-Daniels-1999" TYPE="REFERENCE">Daniels 1999</LINK>) . The Konstam study included individual patient data from 23 phase IIb to V studies in patients with RA, OA and studies in Alzheimers disease and chronic low back pain in trials conducted up to September 2000, which lasted a minimum of four weeks. The comparators used were placebo, diclofenac, ibuprofen, nabumetone or naproxen. The results are difficult to interpret as the data are aggregated with no data from NSAIDs other than naproxen in RA patients . The data are also presented as events per hundred patient years at risk rather than total number of patients with events. Rofecoxib was found to have equivalent rates of CV events compared to placebo or non-naproxen NSAIDs. The authors suggest that the increased MI event is an artefact of the use of naproxen, which unlike other non-aspirin NSAIDs at doses of 500mg twice a day produces reversible antiplatelet effects similar to aspirin throughout the dosing interval. This however has been disputed and the extrapolation of the results to RA patients is complicated by their increased risk of MI.</P>
<P>The Daniels study investigated the overall incidence of thromboembolic cardiovascular events in the heart, brain and arteries (MI/angina CVA, TIA, arterial embolism) (<LINK REF="REF-Daniels-1999" TYPE="REFERENCE">Daniels 1999</LINK>). Data from 7535 patients with osteoarthritis were analysed, including 5,943 patients from 9 RCTs plus unpublished data from 1,592 patients with a mean treatment duration of 5.5 months. Similar rates of MI were found in all groups i.e. rofecoxib vs diclofenac, ibuprofen and nabumetone (NSAIDs that do not produce sustained maximal inhibition of platelet aggregation). Thromboembolic cardiovascular events per 100 patients years were 2.9, 3.0 and 3.0 in the placebo, rofecoxib and NSAID treatment groups respectively. The incidence of cardiac, central nervous and peripheral system events were similar among the treatment groups and cardiovascular deaths per 100 patient years were 0.1 and 0.8 for rofecoxib and NSAIDs. </P>
<P>The adverse effects reported in RCTs give only a part of the picture. In addition to RCT data from rofecoxib in conditions other than rheumatoid arthritis, it may be useful to also review other types of studies of rofecoxib in humans to identify adverse events, and to examine the 'suspected adverse effect' data held by major drug regulatory agencies and the manufacturer. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>It cannot be conclusively stated that rofecoxib has similar efficacy to all other NSAIDs although 50mg has been shown to be about as effective as 1g naproxen per day. No studies were found which evaluated 25mg rofecoxib or it's efficacy against NSAIDs other than naproxen.</P>
<P>The data from the VIGOR study demonstrate that rofecoxib is associated with a reduced incidence of ulceration and GI complications. Whilst this is an important advance, any practitioner also needs to consider the cost-effectiveness of the routine use of rofecoxib as it costs more than standard NSAIDs and the absolute numbers of patients experiencing GI complications remains small. <BR/> <BR/>However, in individuals with risk-factors for GI side-effects (e.g. age, previous history, concomitant medication etc), the evidence suggests that rofecoxib is an alternative to standard NSAID plus gastroprotection with misoprostol. In the absence of any data on the relative clinical or cost-effectiveness of these two strategies, patient choice should be considered in conjunction with the relative side-effect profiles. </P>
<P>Where individuals are taking concomitant aspirin, until further evidence appears to the contrary, prescription of rofecoxib appears to have no benefit. The CLASS study results suggest that the benefits of coxibs in terms of reduced GI complications may not be realised when aspirin is co-prescribed.</P>
<P>In individuals who are also at high risk of a cardio-vascular event, including those in whom aspirin is indicated, given the uncertainty over the cardiovascular safety of rofecoxib, a standard NSAID plus misoprostol should be considered. There is no evidence to support the use of other gastroprotection agents (GPA) such as H2 antagonists or proton pump inhibitors. </P>
<P>Rofecoxib appears to have equivalent renal complications to other NSAIDs and therefore the same precautions need to be applied. This is particularly important in individuals who have a low circulating fluid volume and are sensitive to reductions in GFR, for example individuals with congestive heart failure, those with cirrhosis and those taking a diuretic.</P>
<P>Rofecoxib also has a limited history of use, which means that practitioners need to be alert to rarer side-effects, which will become evident only in the longer-term. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The relative efficacy and safety of rofecoxib versus standard NSAID plus GPA needs to be established. Further studies also need to be conducted to examine the relative benefits and drawbacks of rofecoxib, especially the cardiovascular and renal safety profile and the impact of the concomitant use of aspirin. It also remains to be established whether rofecoxib has a prothrombotic effect and whether there are true differences in antithrombotic effects of different NSAIDs. If rofecoxib does have such an effect then there may be a case for mandatory use of aspirin, which may increase the risk of GI events.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to thank Bev Shea for her editorial support and assistance with quality assessment of the included studies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>SG was responsible for writing the manuscript, extracting and analyzing the data, selecting trials, quality assessment of trials<BR/>RF conducted the search strategies and assisted with data abstraction<BR/>DF assisted with the data abstraction<BR/>DF, RF, TT, MJ, GW and PT contributed methodological expertise and commented on drafts<BR/>MJ and BS conducted quality assessment of trials<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-19 19:03:33 -0400" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bombardier-2000" NAME="Bombardier 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. The VIGOR trial. New England Journal of Medicine 2000; 343(21):1520-1584.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bombardier C, Laine L, Reicin A, et al</AU>
<TI>Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. The VIGOR trial</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>21</NO>
<PG>1520-1584</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnitzer-1999" NAME="Schnitzer 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clinical Therapeutics 1999; 21(10):1688-1702.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q et al</AU>
<TI>The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1688-1702</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjarnason-1998" NAME="Bjarnason 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Bjarnason I SGCReal. COX-2 specific inhibition with MK-096625 or 50 mg Q.D. does not increase intestinal permeability [abstract]. American journal of Gastroenterology 1998; 93(9):1670-Abstract 246.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjarnason I SGCReal</AU>
<TI>COX-2 specific inhibition with MK-096625 or 50 mg Q.D. does not increase intestinal permeability [abstract]</TI>
<SO>American journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>9</NO>
<PG>1670-Abstract 246</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanza-1999" NAME="Lanza 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Alimentary Pharmacology &amp;amp; Therapeutics 1999; 13(6):761-767.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME et al</AU>
<TI>Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>6</NO>
<PG>761-767</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malmstrom-1999" NAME="Malmstrom 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Malmstrom K, Daniels S, Kotey P, Seidenberg B, Desjardins P. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clinical Therapeutics 1999; 21(10):1653-1663.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malmstrom K, Daniels S, Kotey P, Seidenberg B, Desjardins P</AU>
<TI>Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1653-1663</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sigthrosson-2000" NAME="Sigthrosson 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sigthrosson G, Crane R, Simon T, Hoover M et al</AU>
<TI>Cox-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double-blind cross-over study comparing rofecoxib with placebo and indomethacin</TI>
<SO>GUT</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>527-532</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CDER-017" NAME="CDER 017" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>6 week placebo controlled study 137 patients (125mg rofecoxib, 175mg rofecoxib versus placebo). Centre for Drug Evaluation and Research (CDER017) plus extension.</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawkey-2003" NAME="Hawkey 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Phase III endoscopy study. 660 patients enrolled 13 week duration. Rofecoxib 50mg compared to naproxen and placebo. Details in Konstam 2001&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkey CJ, Laine L, Simon T, et al</AU>
<TI>Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen or placebo: a multicentre, randomised, double blind study</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>820-826</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Study-1" NAME="Study 1" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Phase IIb dose finding study. 2 year duration, 634 patients comparing 25 and 50 mg rofecoxib to naproxen and placebo. Details in Konstam 2001</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Study-2" NAME="Study 2" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Phase III: domestic US 1 year duration, 909 patients. Comparing 12.5, 25 and 50mg rofecoxib with naproxen and placebo. Details in Konstam 2001</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Truitt-_x0028_FRI0037_x0029_" NAME="Truitt (FRI0037)" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Phase III international study. 1058 enrolled, 1 year duration. Rofecoxib 25 and 50mg compared to naproxen and placebo. Details in Konstam 2001</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Moots-2001" NAME="Moots 2001" YEAR="2001">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-19 19:03:33 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-19 19:03:33 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Brater-2001" NAME="Brater 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brater DC, Harris C, Redfern JS, Gertz BJ</AU>
<TI>Renal effects of COX-2-selective inhibitors</TI>
<SO>American Journal of Nephrology</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>1-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1999" NAME="Collins 1999" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Peto R, MacMahon S et al</AU>
<TI>Blood presure, stroke and coronary disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>827-838</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daniels-1999" NAME="Daniels 1999" TYPE="JOURNAL_ARTICLE">
<AU>Daniels B, Seidenberg B</AU>
<TI>Cardiovascular safety profile of rofecoxib in controlled clinical trials</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>Suppl 9</NO>
<PG>S143-Abstract 435</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2001" NAME="FDA 2001" TYPE="OTHER">
<AU>FDA Advisory Committee</AU>
<TI>Cardiovascular safety review of rofecoxib</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1993" MODIFIED="2008-05-19 19:03:33 -0400" MODIFIED_BY="[Empty name]" NAME="Felson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M et al</AU>
<TI>The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>729-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1995" MODIFIED="2008-05-19 19:03:12 -0400" MODIFIED_BY="[Empty name]" NAME="Felson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al.</AU>
<TI>American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carrol D, Jenkinson C</AU>
<TI>Assessing the quality of reports of randomised controlled trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Konstam-2001" NAME="Konstam 2001" TYPE="JOURNAL_ARTICLE">
<AU>Konstam M, Weir R, Reicin A, Shapiro D et al</AU>
<TI>Cardiovascular thrombotic events in controlled clinical trials of rofecoxib</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<PG>r15-r23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OMERACT-1993" NAME="OMERACT 1993" TYPE="JOURNAL_ARTICLE">
<AU>OMERACT</AU>
<TI>Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials</TI>
<SO>J Rheumatol</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>526-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pincus-1999" NAME="Pincus 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pincus T, Stein CM</AU>
<TI>ACR20: clinical or statistical significance?</TI>
<SO>Arthritis Rheum</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>8</NO>
<PG>1572-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rocha-2001" MODIFIED="2008-05-19 19:02:30 -0400" MODIFIED_BY="[Empty name]" NAME="Rocha 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rocha JL, Fernandez-Alonso</AU>
<TI>Acute tubulointerstitial nephritis associated wiht the selective COX II enzyme inhibitor rofecoxib</TI>
<SO>The Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>9272</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schultz-1995" NAME="Schultz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman D</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silman-1998" MODIFIED="2008-05-19 19:01:07 -0400" MODIFIED_BY="[Empty name]" NAME="Silman 1998" TYPE="BOOK_SECTION">
<AU>Silman A</AU>
<TI>Epidemiology and rheumatic diseases</TI>
<SO>Oxford Textbook of Rheumatology</SO>
<YR>1998</YR>
<PG>811-28</PG>
<ED>Maddison P, Isenberg D, Woo P, Glass D</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverstein-1995" NAME="Silverstein 1995" TYPE="JOURNAL_ARTICLE">
<AU>Siverstein FE, Graham DY, Senior JR et al</AU>
<TI>Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving NSAIDs: a randomised double-blind, placebo controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1995</YR>
<VL>123</VL>
<PG>241-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverstein-2000" NAME="Silverstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS</AU>
<TI>Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>284</VL>
<NO>10</NO>
<PG>1247-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swan-2000" NAME="Swan 2000" TYPE="JOURNAL_ARTICLE">
<AU>Swan SK, Rudy DW, Lasseter KC, Ryan CF et al</AU>
<TI>Effect of cyclooxygenase -2 inhibition on renal function in elderly persons receiving a low salt diet: a randomised controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>133</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vane-1998" NAME="Vane 1998" TYPE="JOURNAL_ARTICLE">
<AU>Vane JR, Bakhle YS, Botting RM</AU>
<TI>Cyclooxygenases 1 and 2</TI>
<SO>Annual Review of Pharmacology &amp; Toxicology</SO>
<YR>1998</YR>
<VL>38</VL>
<PG>97-120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wallberg-1999" NAME="Wallberg 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wallberg-Jonsson S, Johansson H, Ohman ML</AU>
<TI>Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset</TI>
<SO>Journal of Rheumatology</SO>
<YR>1999</YR>
<VL>26</VL>
<PG>2562-2571</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watson-2000" MODIFIED="2008-05-19 19:01:46 -0400" MODIFIED_BY="[Empty name]" NAME="Watson 2000" TYPE="COCHRANE_REVIEW">
<AU>Watson M, Brooks S, Kirwan J, Faulkner A.</AU>
<TI>Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whelton-2001" MODIFIED="2008-05-19 19:02:24 -0400" MODIFIED_BY="[Empty name]" NAME="Whelton 2001" TYPE="JOURNAL_ARTICLE">
<AU>Whelton A, Fort JG, Puma JA et al</AU>
<TI>Cyclo-oxygenase-2 specific inhibitors and cardio-renal function: a randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients</TI>
<SO>American Journal of Therapeutics</SO>
<YR>2001</YR>
<VL>8</VL>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bombardier-2000">
<CHAR_METHODS>
<P>Randomised 0.5 to 13 months double-blind 301 centre (22 country) <BR/>concomitant DMARDs, MTX and CCX permitted<BR/>paracetamol rescue<BR/>PUBs had to be clinically confirmed using endoscopy, surgery or radiography.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>RA<BR/>N=8076<BR/>&gt;50 yoa or &gt; 40 yoa plus GCX therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>50mg/day rofecoxib<BR/>2 x 500mg/day naproxen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Investigator and patient global assessment of disease activity (0-4); LOE withdrawals; Modified Health Assessment Questionnaire (0-3)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>EFFICACY: No SS differences between comparators: rofecoxib 6.3%, naproxen 6.5%NB: GI event defined as PUB</P>
<P>SAFETY: RR GI withdrawals 0.74 (95% CI: 0.64, 0.85)RR Total AE withdrawals 1.02 (95% CI: 0.92, 1.12) RR confirmed upper GI event 0.46 (95% CI: 0.33,0.64) p&lt;0.001.RR complicated confirmed upper GI event 0.43(95% CI: 0.24,0.78) p=0.005.RR complicated upper GI bleeding 0.4(95% CI: 0.2,0.7) p=0.004.RR bleeding beyond duodenum 0.5 (95% CI: 0.2,0.9) p=0.03.RR all bleeding events 0.38 (95% CI: 0.25, 0.57) p&lt;0.001.RR upper GI events in patients with previous GI events 0.4 (95% CI: 0.2, 0.8)RR patients with glucocorticoid therapy at baseline 0.4 (95% CI: 0.2, 0.6) RR patients with no glucocorticoid therapy at baseline 0.7 (95% CI: 0.4, 1.2) Jadad quality score = 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schnitzer-1999">
<CHAR_METHODS>
<P>8 weeks <BR/>double-blind 79 centre US <BR/>Stable therapy with DMARDs permitted.<BR/>oral CCX or MTX but not both but stratified for MTX<BR/>no SS differences at baseline<BR/>paracetamol rescue</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>RA (ARC criteria)<BR/>N=658<BR/>&gt;18 yoa<BR/>history of therapeutic benefit from NSAIDs and to have used therapeutic NSAIDs for at least 25 of last 30dys preceding study entry</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>rofecoxib 5 or 25 or 50mg/day<BR/>placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P># patients in each group meeting; ACR 20 response; # tender joints /68; #swollen joints/66; patient global assessment of disease activity*; investigator global assessment of disease activity (0-4); patient global pain *; CRP; QOL: Stanford Health Assessment Questionnaire; Disability Index (0-3)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>5mg not SS different from placebo.25mg, 50mg #patients with ARC 20 &gt; placebo (p=0.025, 0.001). Also with patient mean change pain, patient global assessment of disease activity, investigator global assessment of disease activity, SHAQ DI and paracetamol use (p&lt;0.001). Clear separation between 5mg/placebo and higher doses.rofecoxib similar efficacy in patients taking MTX compared to those notQOL: 25mg, 50mg #patients with SHAQ DI (p&lt;0.001).ADRs: only reported those which &gt;3% patient experienced. No SS differences between groups, except greater incidence of rash in 50mg. No difference between groups in the number discontinuing due to GI (3/171 vs 0/168) SHAQ DI= Stanford Health Assessment Questionnaire Disability Index<BR/>Jadad quality score = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RA = rheumatoid arthritis<BR/>OA = osteo arthritis ; N= number of patients enrolled; yoa = years of age; OMs= outcome measures; SS= statistically significant; LOE= lack of efficacy; DMARD= disease modifying antirheumatic agent; CCX= corticosteroids; GCX= glucocorticoids; MTX= methotrexate; *= 100mm Visual Analogue Scale, AE= adverse events; RR = risk ratio; 95% CI= 95% confidence interval; US= United States; UK= United Kingdom; NHP= Nottingham Health Profile; ESR= erythrocyte sedimentation rate; # = number of; HAQ= ; CRP= C-reactive protein</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bjarnason-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lanza-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Healthy volunteers with endpoints of impact on mucosa</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malmstrom-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dental pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sigthrosson-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-CDER-017">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Hawkey-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Study-1">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Study-2">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Truitt-_x0028_FRI0037_x0029_">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Moots-2001">
<CHAR_STUDY_NAME>
<P>Measurement of clinical outcome within clinical service</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients with RA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rofecoxib 25mg, 50mg or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Randomised Controlled Trial and Database Analysis</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>01/06/1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Dr Robert John Moots, Rheumatolgy, Clinical Sciences Centre for Research and Development<BR/>University Teaching Hospital Aintree, Longmoor Lane, Liverpool, L9 7AL<BR/>Telephone: 0151 529 5898, Fax: 0151 529 2420, E-mail: rjmoots@liv.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Anticipated end date 01/12/2001</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bombardier-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schnitzer-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>rofecoxib versus placebo 8 weeks</NAME>
<DICH_OUTCOME CHI2="0.04564274388793291" CI_END="0.9171566158675976" CI_START="0.5409167615479443" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.704347489870854" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="111" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.037556496827975" LOG_CI_START="-0.26686956073764717" LOG_EFFECT_SIZE="-0.1522130287828111" METHOD="MH" NO="1" P_CHI2="0.9774370769607726" P_Q="0.0" P_Z="0.00926918507059781" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="490" TOTAL_2="504" WEIGHT="300.0" Z="2.601963004685884">
<NAME>Withdrawals -all</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.098582657727684" CI_START="0.43300278122465624" DF="0" EFFECT_SIZE="0.6897023605884366" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="37" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.0408327389483861" LOG_CI_START="-0.36350931411628357" LOG_EFFECT_SIZE="-0.16133828758394872" NO="1" P_CHI2="1.0" P_Z="0.1177923085591943" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="168" WEIGHT="100.0" Z="1.5641075697923021">
<NAME>5mg</NAME>
<DICH_DATA CI_END="1.098582657727684" CI_START="0.43300278122465624" EFFECT_SIZE="0.6897023605884366" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="37" LOG_CI_END="0.0408327389483861" LOG_CI_START="-0.36350931411628357" LOG_EFFECT_SIZE="-0.16133828758394872" ORDER="1512" O_E="0.0" SE="0.23751252349562982" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="158" TOTAL_2="168" VAR="0.0564121988172621" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0872122328430331" CI_START="0.4383845705280867" DF="0" EFFECT_SIZE="0.6903745851114272" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.03631433024608922" LOG_CI_START="-0.35814473977102523" LOG_EFFECT_SIZE="-0.160915204762468" NO="2" P_CHI2="1.0" P_Z="0.10980034863901067" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="1.5990911598794861">
<NAME>25mg</NAME>
<DICH_DATA CI_END="1.0872122328430331" CI_START="0.43838457052808666" EFFECT_SIZE="0.6903745851114272" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" LOG_CI_END="0.03631433024608922" LOG_CI_START="-0.3581447397710253" LOG_EFFECT_SIZE="-0.160915204762468" ORDER="1513" O_E="0.0" SE="0.23170721033194083" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="171" TOTAL_2="168" VAR="0.05368823131981027" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.152965349904405" CI_START="0.4663304811833126" DF="0" EFFECT_SIZE="0.7332549941245593" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.061816255628232245" LOG_CI_START="-0.33130619643256" LOG_EFFECT_SIZE="-0.1347449704021639" NO="3" P_CHI2="1.0" P_Z="0.17908496965570106" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="168" WEIGHT="100.0" Z="1.3435777463319103">
<NAME>50mg</NAME>
<DICH_DATA CI_END="1.152965349904405" CI_START="0.46633048118331255" EFFECT_SIZE="0.7332549941245593" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" LOG_CI_END="0.061816255628232245" LOG_CI_START="-0.33130619643256004" LOG_EFFECT_SIZE="-0.1347449704021639" ORDER="1514" O_E="0.0" SE="0.23092207432803158" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="161" TOTAL_2="168" VAR="0.05332500441196094" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1960062748111804" CI_END="0.7898338809095509" CI_START="0.375113008704203" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5443132953038156" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.10246424059635821" LOG_CI_START="-0.42583787450433364" LOG_EFFECT_SIZE="-0.26415105755034596" METHOD="MH" NO="2" P_CHI2="0.5499088712374756" P_Q="0.0" P_Z="0.0013646125965773245" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="490" TOTAL_2="504" WEIGHT="300.0" Z="3.2020332209531843">
<NAME>Withdrawals-due to lack of efficacy</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.284050114106729" CI_START="0.3913270758123837" DF="0" EFFECT_SIZE="0.7088607594936709" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.10858197377590502" LOG_CI_START="-0.40746010234438707" LOG_EFFECT_SIZE="-0.149439064284241" NO="1" P_CHI2="1.0" P_Z="0.25630826838972076" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="168" WEIGHT="100.0" Z="1.135160086489548">
<NAME>5mg</NAME>
<DICH_DATA CI_END="1.284050114106729" CI_START="0.39132707581238374" EFFECT_SIZE="0.7088607594936709" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.10858197377590502" LOG_CI_START="-0.407460102344387" LOG_EFFECT_SIZE="-0.149439064284241" ORDER="1515" O_E="0.0" SE="0.30312566996253393" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="158" TOTAL_2="168" VAR="0.09188517179023506" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.889837353890149" CI_START="0.227865511045022" DF="0" EFFECT_SIZE="0.4502923976608187" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.05068936724625044" LOG_CI_START="-0.6423214031930935" LOG_EFFECT_SIZE="-0.346505385219672" NO="2" P_CHI2="1.0" P_Z="0.02168661143240007" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="2.2958123773431156">
<NAME>25mg</NAME>
<DICH_DATA CI_END="0.8898373538901488" CI_START="0.227865511045022" EFFECT_SIZE="0.4502923976608187" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.0506893672462505" LOG_CI_START="-0.6423214031930935" LOG_EFFECT_SIZE="-0.346505385219672" ORDER="1516" O_E="0.0" SE="0.34752758654098576" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="171" TOTAL_2="168" VAR="0.12077542340700234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9441384946678634" CI_START="0.24226685030753206" DF="0" EFFECT_SIZE="0.4782608695652174" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-0.02496429483505997" LOG_CI_START="-0.6157060068836756" LOG_EFFECT_SIZE="-0.3203351508593678" NO="3" P_CHI2="1.0" P_Z="0.03353515002053278" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="168" WEIGHT="99.99999999999999" Z="2.1256171550482854">
<NAME>50mg</NAME>
<DICH_DATA CI_END="0.9441384946678633" CI_START="0.24226685030753206" EFFECT_SIZE="0.4782608695652174" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.02496429483506002" LOG_CI_START="-0.6157060068836756" LOG_EFFECT_SIZE="-0.3203351508593678" ORDER="1517" O_E="0.0" SE="0.34700460587599263" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="161" TOTAL_2="168" VAR="0.120412196499153" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6733800739257753" CI_END="2.984904400967296" CI_START="0.831754367672616" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5756609002541637" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.47493042632058635" LOG_CI_START="-0.08000490990472385" LOG_EFFECT_SIZE="0.19746275820793122" METHOD="MH" NO="3" P_CHI2="0.7141302320874996" P_Q="0.0" P_Z="0.1630674720890365" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="490" TOTAL_2="504" WEIGHT="300.0" Z="1.394828799362496">
<NAME>Withdrawals-due to all adverse events</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.603049706417027" CI_START="0.31378641398529633" DF="0" EFFECT_SIZE="1.0632911392405062" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.5566702535390893" LOG_CI_START="-0.5033658639962089" LOG_EFFECT_SIZE="0.026652194771440187" NO="1" P_CHI2="1.0" P_Z="0.9214894853728236" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="168" WEIGHT="100.00000000000001" Z="0.09855766420945569">
<NAME>5mg</NAME>
<DICH_DATA CI_END="3.603049706417027" CI_START="0.31378641398529633" EFFECT_SIZE="1.0632911392405062" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5566702535390893" LOG_CI_START="-0.5033658639962089" LOG_EFFECT_SIZE="0.026652194771440187" ORDER="1518" O_E="0.0" SE="0.6226704627036427" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="158" TOTAL_2="168" VAR="0.3877185051235685" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.707622896971747" CI_START="0.5248855797126679" DF="0" EFFECT_SIZE="1.5719298245614035" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.6728016665070738" LOG_CI_START="-0.2799353585278063" LOG_EFFECT_SIZE="0.1964331539896338" NO="2" P_CHI2="1.0" P_Z="0.418974407501568" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="0.8082018375956315">
<NAME>25mg</NAME>
<DICH_DATA CI_END="4.707622896971747" CI_START="0.5248855797126679" EFFECT_SIZE="1.5719298245614035" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6728016665070738" LOG_CI_START="-0.2799353585278063" LOG_EFFECT_SIZE="0.1964331539896338" ORDER="1519" O_E="0.0" SE="0.5596424446298233" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="171" TOTAL_2="168" VAR="0.3131996658312448" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.972915246601654" CI_START="0.7291895739032173" DF="0" EFFECT_SIZE="2.0869565217391304" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.7761863523170757" LOG_CI_START="-0.13715954960108692" LOG_EFFECT_SIZE="0.31951340135799433" NO="3" P_CHI2="1.0" P_Z="0.17028204143640982" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="168" WEIGHT="100.0" Z="1.3712981202945649">
<NAME>50mg</NAME>
<DICH_DATA CI_END="5.972915246601655" CI_START="0.729189573903217" EFFECT_SIZE="2.0869565217391304" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7761863523170757" LOG_CI_START="-0.13715954960108706" LOG_EFFECT_SIZE="0.31951340135799433" ORDER="1520" O_E="0.0" SE="0.5365039039218592" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="161" TOTAL_2="168" VAR="0.2878364389233955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.014316322551615975" CI_END="50.6467482680574" CI_START="0.7375201062374952" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="6.111709675961495" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.7045515670788622" LOG_CI_START="-0.13222613547323145" LOG_EFFECT_SIZE="0.7861627158028154" METHOD="MH" NO="4" P_CHI2="0.9047597503159237" P_Q="0.0" P_Z="0.0933908712380504" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="490" TOTAL_2="504" WEIGHT="200.0" Z="1.677775821016115">
<NAME>Withdrawals - due to GI</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="109.84433379222078" CI_START="0.25712334543181925" DF="0" EFFECT_SIZE="5.314465408805032" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="2.040777659196996" LOG_CI_START="-0.5898584899385139" LOG_EFFECT_SIZE="0.7254595846292409" NO="1" P_CHI2="1.0" P_Z="0.27969178022724095" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="168" WEIGHT="100.0" Z="1.0810120271326478">
<NAME>5mg</NAME>
<DICH_DATA CI_END="109.84433379222068" CI_START="0.25712334543181936" EFFECT_SIZE="5.314465408805032" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0407776591969955" LOG_CI_START="-0.5898584899385136" LOG_EFFECT_SIZE="0.7254595846292409" ORDER="1521" O_E="0.0" SE="1.5452486958611502" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="158" TOTAL_2="168" VAR="2.3877935320605856" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="132.14338052385216" CI_START="0.35798693958951344" DF="0" EFFECT_SIZE="6.877906976744186" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="2.1210454128406626" LOG_CI_START="-0.4461328173998999" LOG_EFFECT_SIZE="0.8374562977203814" NO="2" P_CHI2="1.0" P_Z="0.2009866136033338" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="1.2787457939797124">
<NAME>25mg</NAME>
<DICH_DATA CI_END="132.14338052385216" CI_START="0.35798693958951344" EFFECT_SIZE="6.877906976744186" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1210454128406626" LOG_CI_START="-0.4461328173998999" LOG_EFFECT_SIZE="0.8374562977203814" ORDER="1522" O_E="0.0" SE="1.507973200180494" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="171" TOTAL_2="168" VAR="2.2739831724626" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="168" WEIGHT="0.0" Z="0.0">
<NAME>50mg</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1523" O_E="0.0" SE="0.0" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="161" TOTAL_2="168" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.292284994638732" CI_END="4.380997366199428" CI_START="0.623690194076871" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6529927699706317" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="12.750813939904381" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.641572992085868" LOG_CI_START="-0.20503108405818848" LOG_EFFECT_SIZE="0.21827095401383975" METHOD="MH" NO="5" P_CHI2="0.317860937524731" P_Q="0.0" P_Z="0.312191902759829" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="490" TOTAL_2="504" WEIGHT="300.0" Z="1.0106334727014241">
<NAME>Adverse events-Hypertension</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.393773351688829" CI_START="0.010284933817272777" DF="0" EFFECT_SIZE="0.21257861635220127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.6428376505249579" LOG_CI_START="-1.9877984986105512" LOG_EFFECT_SIZE="-0.6724804240427967" NO="1" P_CHI2="1.0" P_Z="0.3163110372760817" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="168" WEIGHT="100.0" Z="1.0020674367036613">
<NAME>5mg</NAME>
<DICH_DATA CI_END="4.393773351688829" CI_START="0.010284933817272777" EFFECT_SIZE="0.21257861635220127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6428376505249579" LOG_CI_START="-1.9877984986105512" LOG_EFFECT_SIZE="-0.6724804240427967" ORDER="1524" O_E="0.0" SE="1.5452486958611502" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="158" TOTAL_2="168" VAR="2.3877935320605856" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.48507793862511" CI_START="0.4831868453575285" DF="0" EFFECT_SIZE="2.456140350877193" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.0963912577974317" LOG_CI_START="-0.3158848977859383" LOG_EFFECT_SIZE="0.39025318000574666" NO="2" P_CHI2="1.0" P_Z="0.27872381671534996" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="1.0831906700960194">
<NAME>25mg</NAME>
<DICH_DATA CI_END="12.48507793862511" CI_START="0.4831868453575285" EFFECT_SIZE="2.456140350877193" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0963912577974317" LOG_CI_START="-0.3158848977859383" LOG_EFFECT_SIZE="0.39025318000574666" ORDER="1525" O_E="0.0" SE="0.829578004669389" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="171" TOTAL_2="168" VAR="0.6881996658312448" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.254859243757942" CI_START="0.5134187304837559" DF="0" EFFECT_SIZE="2.608695652173913" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="1.122375120225748" LOG_CI_START="-0.28952829149364645" LOG_EFFECT_SIZE="0.41642341436605074" NO="3" P_CHI2="1.0" P_Z="0.24762629819317916" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="168" WEIGHT="100.0" Z="1.1561341770294806">
<NAME>50mg</NAME>
<DICH_DATA CI_END="13.254859243757942" CI_START="0.5134187304837559" EFFECT_SIZE="2.608695652173913" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.122375120225748" LOG_CI_START="-0.28952829149364645" LOG_EFFECT_SIZE="0.41642341436605074" ORDER="1526" O_E="0.0" SE="0.8293590530785779" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="161" TOTAL_2="168" VAR="0.6878364389233954" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3084862006024295" CI_END="4.675426151687905" CI_START="0.6252292338446777" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7097406559818358" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.6698212017094375" LOG_CI_START="-0.20396072387004843" LOG_EFFECT_SIZE="0.23293023891969453" METHOD="MH" NO="6" P_CHI2="0.8570636596437489" P_Q="0.0" P_Z="0.29604009820790056" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="490" TOTAL_2="504" WEIGHT="300.0" Z="1.0449629726321943">
<NAME>Adverse events -Lower extremity oedema</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.457797314723035" CI_START="0.1515981192671178" DF="0" EFFECT_SIZE="1.0632911392405062" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.8726105760897166" LOG_CI_START="-0.8193061865468362" LOG_EFFECT_SIZE="0.026652194771440187" NO="1" P_CHI2="1.0" P_Z="0.9507624753710701" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="168" WEIGHT="100.0" Z="0.061749304711145314">
<NAME>5mg</NAME>
<DICH_DATA CI_END="7.457797314723035" CI_START="0.1515981192671178" EFFECT_SIZE="1.0632911392405062" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8726105760897166" LOG_CI_START="-0.8193061865468362" LOG_EFFECT_SIZE="0.026652194771440187" ORDER="1527" O_E="0.0" SE="0.9938402814957584" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="158" TOTAL_2="168" VAR="0.9877185051235684" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.584812321553095" CI_START="0.36475661103512763" DF="0" EFFECT_SIZE="1.9649122807017543" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="1.0246831619835401" LOG_CI_START="-0.4379968279881599" LOG_EFFECT_SIZE="0.2933431669976902" NO="2" P_CHI2="1.0" P_Z="0.43178033807134075" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="0.7861487767225356">
<NAME>25mg</NAME>
<DICH_DATA CI_END="10.584812321553095" CI_START="0.36475661103512763" EFFECT_SIZE="1.9649122807017543" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0246831619835401" LOG_CI_START="-0.4379968279881599" LOG_EFFECT_SIZE="0.2933431669976902" ORDER="1528" O_E="0.0" SE="0.8591854664920985" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="171" TOTAL_2="168" VAR="0.7381996658312449" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.237596868255311" CI_START="0.38757285696311716" DF="0" EFFECT_SIZE="2.0869565217391304" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="1.050673448382436" LOG_CI_START="-0.4116466456664475" LOG_EFFECT_SIZE="0.31951340135799433" NO="3" P_CHI2="1.0" P_Z="0.3917241710091688" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="168" WEIGHT="100.0" Z="0.8564947740075654">
<NAME>50mg</NAME>
<DICH_DATA CI_END="11.237596868255311" CI_START="0.38757285696311716" EFFECT_SIZE="2.0869565217391304" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.050673448382436" LOG_CI_START="-0.4116466456664475" LOG_EFFECT_SIZE="0.31951340135799433" ORDER="1529" O_E="0.0" SE="0.8589740618455225" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="161" TOTAL_2="168" VAR="0.7378364389233955" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.4214467397977" CI_END="1.5432892585041689" CI_START="1.1334281216411233" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3225760641321551" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="174" I2="54.76593708575333" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.18844733345049916" LOG_CI_START="0.05439398377931746" LOG_EFFECT_SIZE="0.12142065861490836" METHOD="MH" NO="7" P_CHI2="0.10962142111029882" P_Q="0.0" P_Z="3.844585375186653E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="490" TOTAL_2="504" WEIGHT="300.0" Z="3.550528479118094">
<NAME>Efficacy -ACR 20 responders</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rofecoxib</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.380348752200894" CI_START="0.7635467438371148" DF="0" EFFECT_SIZE="1.0266259275425578" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="58" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.13998882699621387" LOG_CI_START="-0.11716437056680719" LOG_EFFECT_SIZE="0.011412228214703337" NO="1" P_CHI2="1.0" P_Z="0.861894629646597" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="168" WEIGHT="100.0" Z="0.17396288668499812">
<NAME>5mg</NAME>
<DICH_DATA CI_END="1.380348752200894" CI_START="0.7635467438371148" EFFECT_SIZE="1.0266259275425578" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="58" LOG_CI_END="0.13998882699621387" LOG_CI_START="-0.11716437056680719" LOG_EFFECT_SIZE="0.011412228214703337" ORDER="1530" O_E="0.0" SE="0.15105306117737602" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="158" TOTAL_2="168" VAR="0.0228170272910561" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8019371677177896" CI_START="1.0706768608787394" DF="0" EFFECT_SIZE="1.3889897156684816" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="58" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.25573964336380134" LOG_CI_START="0.029658416945175535" LOG_EFFECT_SIZE="0.14269903015448845" NO="2" P_CHI2="1.0" P_Z="0.01335353335441741" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="2.4741988900370777">
<NAME>25mg</NAME>
<DICH_DATA CI_END="1.8019371677177896" CI_START="1.0706768608787394" EFFECT_SIZE="1.3889897156684816" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="58" LOG_CI_END="0.25573964336380134" LOG_CI_START="0.029658416945175535" LOG_EFFECT_SIZE="0.14269903015448845" ORDER="1531" O_E="0.0" SE="0.1328012315184205" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="171" TOTAL_2="168" VAR="0.01763616709280912" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.993297851342725" CI_START="1.2009793169736334" DF="0" EFFECT_SIZE="1.5472263868065967" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="58" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.2995721986149634" LOG_CI_START="0.07953552813432381" LOG_EFFECT_SIZE="0.18955386337464358" NO="3" P_CHI2="1.0" P_Z="7.331295552910551E-4" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="168" WEIGHT="100.0" Z="3.3768802675771834">
<NAME>50mg</NAME>
<DICH_DATA CI_END="1.993297851342725" CI_START="1.2009793169736334" EFFECT_SIZE="1.5472263868065967" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="58" LOG_CI_END="0.2995721986149634" LOG_CI_START="0.07953552813432381" LOG_EFFECT_SIZE="0.18955386337464358" ORDER="1532" O_E="0.0" SE="0.129250629439413" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="161" TOTAL_2="168" VAR="0.01670572521048446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8445191434497408" CI_END="1.7603042969869278" CI_START="0.9856667102509283" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3172218284904325" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.24558774910909628" LOG_CI_START="-0.00626991098988847" LOG_EFFECT_SIZE="0.11965891905960391" METHOD="MH" NO="8" P_CHI2="0.6555638687051145" P_Q="0.0" P_Z="0.06254972822405154" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="142" TOTAL_2="150" WEIGHT="300.0" Z="1.862378707827616">
<NAME>Efficacy -ACR 20 responders: methotrexate users</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rofecoxib</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9119372075173569" CI_START="0.6141259077889579" DF="0" EFFECT_SIZE="1.08359133126935" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.2814736249293468" LOG_CI_START="-0.21174258089100126" LOG_EFFECT_SIZE="0.03486552201917278" NO="1" P_CHI2="1.0" P_Z="0.7817031286585806" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="50" WEIGHT="100.0" Z="0.27710025199235916">
<NAME>5mg</NAME>
<DICH_DATA CI_END="1.9119372075173566" CI_START="0.614125907788958" EFFECT_SIZE="1.08359133126935" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.28147362492934674" LOG_CI_START="-0.21174258089100118" LOG_EFFECT_SIZE="0.03486552201917278" ORDER="1533" O_E="0.0" SE="0.28971764075846657" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="38" TOTAL_2="50" VAR="0.0839363113666519" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1293037752121338" CI_START="0.8024897714786636" DF="0" EFFECT_SIZE="1.3071895424836601" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.3282376240908512" LOG_CI_START="-0.09556049439808638" LOG_EFFECT_SIZE="0.1163385648463824" NO="2" P_CHI2="1.0" P_Z="0.2818934849632073" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="50" WEIGHT="100.00000000000001" Z="1.076075551845279">
<NAME>25mg</NAME>
<DICH_DATA CI_END="2.1293037752121338" CI_START="0.8024897714786636" EFFECT_SIZE="1.3071895424836601" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.3282376240908512" LOG_CI_START="-0.09556049439808638" LOG_EFFECT_SIZE="0.1163385648463824" ORDER="1534" O_E="0.0" SE="0.24894111263492186" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="54" TOTAL_2="50" VAR="0.061971677559912855" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4448574986254954" CI_START="0.956743019720294" DF="0" EFFECT_SIZE="1.5294117647058822" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.3882535508362565" LOG_CI_START="-0.0192046976511685" LOG_EFFECT_SIZE="0.184524426592544" NO="3" P_CHI2="1.0" P_Z="0.07586382539848628" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.77520632718497">
<NAME>50mg</NAME>
<DICH_DATA CI_END="2.4448574986254954" CI_START="0.956743019720294" EFFECT_SIZE="1.5294117647058822" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.3882535508362565" LOG_CI_START="-0.0192046976511685" LOG_EFFECT_SIZE="0.184524426592544" ORDER="1535" O_E="0.0" SE="0.23934299211237242" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.05728506787330316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5867186040693415" CI_END="1.6457707636710412" CI_START="1.1018986398748127" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3466523552999312" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="108" I2="22.68196483167264" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.2163693430233433" LOG_CI_START="0.042141646995232915" LOG_EFFECT_SIZE="0.1292554950092881" METHOD="MH" NO="9" P_CHI2="0.2743477472042396" P_Q="0.0" P_Z="0.003636275846051363" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="346" TOTAL_2="351" WEIGHT="300.0" Z="2.908103829614179">
<NAME>Efficacy -ACR 20 responders: methotrexate nonusers</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rofecoxib</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5362935475490458" CI_START="0.7262050044276336" DF="0" EFFECT_SIZE="1.05625" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.18647420651596117" LOG_CI_START="-0.13894076260046376" LOG_EFFECT_SIZE="0.02376672195774872" NO="1" P_CHI2="1.0" P_Z="0.7746541656602745" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="117" WEIGHT="100.0" Z="0.2862924173048659">
<NAME>5mg</NAME>
<DICH_DATA CI_END="1.5362935475490458" CI_START="0.7262050044276336" EFFECT_SIZE="1.05625" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" LOG_CI_END="0.18647420651596117" LOG_CI_START="-0.13894076260046376" LOG_EFFECT_SIZE="0.02376672195774872" ORDER="1536" O_E="0.0" SE="0.19115036368906424" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="120" TOTAL_2="117" VAR="0.036538461538461534" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.990201451672892" CI_START="1.0032611873422308" DF="0" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="36" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.2988970386819907" LOG_CI_START="0.001414011240572407" LOG_EFFECT_SIZE="0.1501555249612815" NO="2" P_CHI2="1.0" P_Z="0.047861467260694256" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="117" WEIGHT="100.0" Z="1.9785963826912556">
<NAME>25mg</NAME>
<DICH_DATA CI_END="1.990201451672892" CI_START="1.0032611873422308" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="36" LOG_CI_END="0.2988970386819907" LOG_CI_START="0.001414011240572407" LOG_EFFECT_SIZE="0.1501555249612815" ORDER="1537" O_E="0.0" SE="0.1747430028838242" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="115" TOTAL_2="117" VAR="0.03053511705685619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.204235450104091" CI_START="1.1340972602697552" DF="0" EFFECT_SIZE="1.5810810810810811" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="36" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.3432579827475787" LOG_CI_START="0.05465030128279227" LOG_EFFECT_SIZE="0.19895414201518546" NO="3" P_CHI2="1.0" P_Z="0.00688749716350671" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="117" WEIGHT="100.0" Z="2.702235442561555">
<NAME>50mg</NAME>
<DICH_DATA CI_END="2.204235450104091" CI_START="1.1340972602697552" EFFECT_SIZE="1.5810810810810811" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="36" LOG_CI_END="0.3432579827475787" LOG_CI_START="0.05465030128279227" LOG_EFFECT_SIZE="0.19895414201518546" ORDER="1538" O_E="0.0" SE="0.16952958072347946" STUDY_ID="STD-Schnitzer-1999" TOTAL_1="111" TOTAL_2="117" VAR="0.02874027874027874" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>rofecoxib versus naproxen 9 months</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1186" EVENTS_2="1148" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals -all</NAME>
<GROUP_LABEL_1>Rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naproxen</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1013498551107657" CI_START="0.960480227608714" EFFECT_SIZE="1.0285060814179041" ESTIMABLE="YES" EVENTS_1="1186" EVENTS_2="1148" LOG_CI_END="0.04192529899794667" LOG_CI_START="-0.017511571071746265" LOG_EFFECT_SIZE="0.012206863963100207" ORDER="1539" O_E="0.0" SE="0.03491351169618956" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.0012189532989599651" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="255" EVENTS_2="262" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals -due to lack of efficacy</NAME>
<GROUP_LABEL_1>Rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naproxen</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1448418091458539" CI_START="0.820087935478808" EFFECT_SIZE="0.9689535364052535" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="262" LOG_CI_END="0.05874548129485548" LOG_CI_START="-0.08613957707281392" LOG_EFFECT_SIZE="-0.013697047888979193" ORDER="1540" O_E="0.0" SE="0.08510620047777466" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.007243065359763171" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.098448986068863" CI_END="0.9467183122568101" CI_START="0.8145520471689675" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8781522301635033" ESTIMABLE="YES" EVENTS_1="1122" EVENTS_2="1272" I2="88.94932929589997" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.023779222296199276" LOG_CI_START="-0.08908116049468351" LOG_EFFECT_SIZE="-0.05643019139544139" METHOD="MH" NO="3" P_CHI2="1.1748278946555057E-4" P_Q="0.0" P_Z="7.056434190902628E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12141" TOTAL_2="12087" WEIGHT="300.0" Z="3.3873770312788194">
<NAME>Withdrawals -due to adverse events</NAME>
<GROUP_LABEL_1>Rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1245639411657355" CI_START="0.9225517505453906" DF="0" EFFECT_SIZE="1.0185619433901274" ESTIMABLE="YES" EVENTS_1="664" EVENTS_2="649" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.050984153863219146" LOG_CI_START="-0.035009262734300516" LOG_EFFECT_SIZE="0.007987445564459333" NO="1" P_CHI2="1.0" P_Z="0.7157832656060253" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="100.0" Z="0.36410009636170326">
<NAME>Withdrawls from all adverse events</NAME>
<DICH_DATA CI_END="1.1245639411657355" CI_START="0.9225517505453906" EFFECT_SIZE="1.0185619433901274" ESTIMABLE="YES" EVENTS_1="664" EVENTS_2="649" LOG_CI_END="0.050984153863219146" LOG_CI_START="-0.035009262734300516" LOG_EFFECT_SIZE="0.007987445564459333" ORDER="1541" O_E="0.0" SE="0.05051295858366038" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.002551558984874589" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0581126819053883E-30" CI_END="0.8911831393620714" CI_START="0.583748410093521" DF="0" EFFECT_SIZE="0.7212674543501613" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="196" I2="100.0" ID="CMP-002.03.02" LOG_CI_END="-0.05003303867761939" LOG_CI_START="-0.2337742892755974" LOG_EFFECT_SIZE="-0.14190366397660836" NO="2" P_CHI2="0.0" P_Z="0.002466945011245852" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="99.99999999999999" Z="3.027366688354161">
<NAME>Withdrawls from GI symptoms (dyspepsia, pain, discomfort, nausea, heartburn)</NAME>
<DICH_DATA CI_END="0.8911831393620713" CI_START="0.583748410093521" EFFECT_SIZE="0.7212674543501612" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="196" LOG_CI_END="-0.05003303867761944" LOG_CI_START="-0.2337742892755974" LOG_EFFECT_SIZE="-0.14190366397660845" ORDER="1542" O_E="0.0" SE="0.10793052013511152" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.011648997176635712" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.846407618440626" CI_START="0.641308472334581" DF="0" EFFECT_SIZE="0.736755303173658" ESTIMABLE="YES" EVENTS_1="316" EVENTS_2="427" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="-0.07242043624481326" LOG_CI_START="-0.19293302257480457" LOG_EFFECT_SIZE="-0.13267672940980893" NO="3" P_CHI2="1.0" P_Z="1.591753275278538E-5" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="100.0" Z="4.315592572509192">
<NAME>Withdrawls from GI symptoms and events</NAME>
<DICH_DATA CI_END="0.846407618440626" CI_START="0.641308472334581" EFFECT_SIZE="0.736755303173658" ESTIMABLE="YES" EVENTS_1="316" EVENTS_2="427" LOG_CI_END="-0.07242043624481326" LOG_CI_START="-0.19293302257480457" LOG_EFFECT_SIZE="-0.13267672940980893" ORDER="1543" O_E="0.0" SE="0.07078968975716024" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.0050111801759149975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6663638705951808" CI_END="0.5245241268519009" CI_START="0.36196153942076154" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.435726474314615" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="361" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.2802345305063481" LOG_CI_START="-0.4413375734025001" LOG_EFFECT_SIZE="-0.36078605195442415" METHOD="MH" NO="4" P_CHI2="0.8810855262186331" P_Q="0.0" P_Z="1.6555712045409446E-18" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16188" TOTAL_2="16116" WEIGHT="400.0" Z="8.778576186309369">
<NAME>Adverse events -Incidence of GI events</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naproxen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6305636470294094" CI_START="0.3366700705456327" DF="0" EFFECT_SIZE="0.46075145960582986" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="121" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-0.2002710706157352" LOG_CI_START="-0.47279549001114185" LOG_EFFECT_SIZE="-0.33653328031343854" NO="1" P_CHI2="1.0" P_Z="1.2943690786814021E-6" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="100.0" Z="4.840616561824181">
<NAME>Confirmed upper GI event (perforation and/or ulcer and/or obstruction and/or bleed)</NAME>
<DICH_DATA CI_END="0.6305636470294093" CI_START="0.3366700705456328" EFFECT_SIZE="0.46075145960582986" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="121" LOG_CI_END="-0.2002710706157353" LOG_CI_START="-0.4727954900111417" LOG_EFFECT_SIZE="-0.33653328031343854" ORDER="1544" O_E="0.0" SE="0.16008219297049447" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.02562630850624263" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7726190549352073" CI_START="0.23988286566386713" DF="0" EFFECT_SIZE="0.4305090858093082" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="37" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.11203458514904874" LOG_CI_START="-0.6200007716794694" LOG_EFFECT_SIZE="-0.36601767841425914" NO="2" P_CHI2="1.0" P_Z="0.004735082930394716" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="100.0" Z="2.824524491666925">
<NAME>Complicated confirmed upper GI POBs (perforation and/or obstruction and/or bleed)</NAME>
<DICH_DATA CI_END="0.7726190549352074" CI_START="0.23988286566386707" EFFECT_SIZE="0.4305090858093082" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="37" LOG_CI_END="-0.11203458514904868" LOG_CI_START="-0.6200007716794695" LOG_EFFECT_SIZE="-0.36601767841425914" ORDER="1545" O_E="0.0" SE="0.2983818524411454" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.08903172986620946" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5676439122630991" CI_START="0.24954439767122716" DF="0" EFFECT_SIZE="0.37636731815798513" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="82" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="-0.24592401540645326" LOG_CI_START="-0.6028521756988127" LOG_EFFECT_SIZE="-0.4243880955526329" NO="3" P_CHI2="1.0" P_Z="3.149827016297864E-6" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="100.0" Z="4.660799988823462">
<NAME>All episodes GI bleed</NAME>
<DICH_DATA CI_END="0.5676439122630991" CI_START="0.2495443976712272" EFFECT_SIZE="0.37636731815798513" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="82" LOG_CI_END="-0.24592401540645326" LOG_CI_START="-0.6028521756988126" LOG_EFFECT_SIZE="-0.4243880955526329" ORDER="1546" O_E="0.0" SE="0.20966136817862027" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.04395788930653096" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6205318386553111" CI_START="0.330003613119854" DF="0" EFFECT_SIZE="0.45252375497001146" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="121" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="-0.20723593052693495" LOG_CI_START="-0.48148130512385534" LOG_EFFECT_SIZE="-0.3443586178253951" NO="4" P_CHI2="1.0" P_Z="8.562392133360587E-7" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="100.0" Z="4.922092047647218">
<NAME>Confirmed upper GI PUBs (performation and/or ulcer and/or bleed)</NAME>
<DICH_DATA CI_END="0.6205318386553111" CI_START="0.330003613119854" EFFECT_SIZE="0.45252375497001146" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="121" LOG_CI_END="-0.20723593052693495" LOG_CI_START="-0.48148130512385534" LOG_EFFECT_SIZE="-0.3443586178253951" ORDER="1547" O_E="0.0" SE="0.16109309057472937" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.025950983830917956" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="129" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36423" TOTAL_2="36261" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events- Cardiovascular Thrombotic</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="19" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Total cardiovascular thrombotic</NAME>
<DICH_DATA CI_END="4.064296379160806" CI_START="1.3856930283376279" EFFECT_SIZE="2.3731555274994083" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="19" LOG_CI_END="0.6089853703242947" LOG_CI_START="0.14166703196071412" LOG_EFFECT_SIZE="0.3753262011425044" ORDER="1548" O_E="0.0" SE="0.27450510521785" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.0753530527906629" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Fatal MI/Sudden death</NAME>
<DICH_DATA CI_END="4.63871239528754" CI_START="0.33401173887009583" EFFECT_SIZE="1.244742701632855" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6663974466701649" LOG_CI_START="-0.4762382696048478" LOG_EFFECT_SIZE="0.09507958853265852" ORDER="1549" O_E="0.0" SE="0.671189875877959" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.4504958494810699" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="4" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Non-fatal MI</NAME>
<DICH_DATA CI_END="13.294827961431906" CI_START="1.5201258361302055" EFFECT_SIZE="4.495532390171259" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="1.1236827218192058" LOG_CI_START="0.1818795403625008" LOG_EFFECT_SIZE="0.6527811310908532" ORDER="1550" O_E="0.0" SE="0.5532198507886045" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.30605220330656574" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-002.05.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Unstable angina</NAME>
<DICH_DATA CI_END="12.845285495669096" CI_START="0.48295525614535423" EFFECT_SIZE="2.4907224146462146" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.108743761215507" LOG_CI_START="-0.3160931030151391" LOG_EFFECT_SIZE="0.396325329100184" ORDER="1551" O_E="0.0" SE="0.8369562271053097" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.7004957260903547" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="10" I2="0.0" ID="CMP-002.05.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Total cardiac events</NAME>
<DICH_DATA CI_END="5.771784773546836" CI_START="1.358332007792837" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.7613101281380715" LOG_CI_START="0.13300593454636683" LOG_EFFECT_SIZE="0.4471580313422192" ORDER="1552" O_E="0.0" SE="0.3690689934716856" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.1362119219422031" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.05.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>TIA</NAME>
<DICH_DATA CI_END="103.76736750084669" CI_START="0.23902158321278077" EFFECT_SIZE="4.980224941292795" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.016060799153241" LOG_CI_START="-0.6215628812820043" LOG_EFFECT_SIZE="0.6972489589356182" ORDER="1553" O_E="0.0" SE="1.5493532063354527" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="2.400495357981948" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-002.05.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Ischemic stroke</NAME>
<DICH_DATA CI_END="2.9064602808468876" CI_START="0.43179356874404495" EFFECT_SIZE="1.1202637444279346" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.46336439234422583" LOG_CI_START="-0.364723830458882" LOG_EFFECT_SIZE="0.04932028094267192" ORDER="1554" O_E="0.0" SE="0.4864231211773579" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.2366074528159226" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-002.05.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Total cerebrovascular</NAME>
<DICH_DATA CI_END="3.409255531240663" CI_START="0.5504421387352721" EFFECT_SIZE="1.3698897423191279" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5326595537805863" LOG_CI_START="-0.25928832637194693" LOG_EFFECT_SIZE="0.13668561370431964" ORDER="1555" O_E="0.0" SE="0.46519410500682906" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.21640555533310468" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-002.05.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Peripheral thrombotic</NAME>
<DICH_DATA CI_END="49.69925962057765" CI_START="0.7197038147246102" EFFECT_SIZE="5.980697847067558" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6963499190131577" LOG_CI_START="-0.1428461953680057" LOG_EFFECT_SIZE="0.7767518618225759" ORDER="1556" O_E="0.0" SE="1.0803529017550917" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="1.1671623923306467" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events -Renal function</NAME>
<GROUP_LABEL_1>rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naproxen</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.078952814419232" CI_START="0.8832235738658948" EFFECT_SIZE="1.3550572440490898" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="36" LOG_CI_END="0.3178446323473867" LOG_CI_START="-0.05392934783131171" LOG_EFFECT_SIZE="0.13195764225803747" ORDER="1557" O_E="0.0" SE="0.21838187626784947" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" VAR="0.04769064388226631" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="4047" TOTAL_2="4029" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Efficacy -Patient Global Disease Activity (0 to 4)</NAME>
<GROUP_LABEL_1>Rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.020785332464585513" CI_START="-0.06078533246458555" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.51" MEAN_2="0.53" ORDER="1558" SD_1="0.93" SD_2="0.94" SE="0.020809225468577497" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="4047" TOTAL_2="4029" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Efficacy -Investigator Global Disease Activity (0 to 4)</NAME>
<GROUP_LABEL_1>Rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.006859636613991173" CI_START="-0.06685963661399122" EFFECT_SIZE="-0.030000000000000027" ESTIMABLE="YES" MEAN_1="0.49" MEAN_2="0.52" ORDER="1559" SD_1="0.84" SD_2="0.85" SE="0.018806282617810994" STUDY_ID="STD-Bombardier-2000" TOTAL_1="4047" TOTAL_2="4029" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.09" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1735" TOTAL_2="1732" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Efficacy -Modified Health Assessment Score (0 to 3)</NAME>
<GROUP_LABEL_1>Rofecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Rofecoxib</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.014301315862079327" CI_START="-0.03430131586207932" EFFECT_SIZE="-0.009999999999999995" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.12" ORDER="1560" SD_1="0.37" SD_2="0.36" SE="0.012398858373809416" STUDY_ID="STD-Bombardier-2000" TOTAL_1="1735" TOTAL_2="1732" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>